Levocetirizine
XYZAL
What it isSecond-generation H1 antagonist and active cetirizine enantiomer; allergic rhinitis and urticaria.
Why this oneIt removes cetirizine's inactive enantiomer but offers little practical efficacy advantage over the parent drug.
What limits itSedation is more common than with loratadine or fexofenadine; renal clearance requires adjustment in impairment.
FDA-approved for
- allergy (2007)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Allergy symptom relief | Adults & children ≥12 yr | 5 mg QHS | 5 mg (or 2.5 mg for less severe) QHS | 5 mg/24h |
| Allergy symptom relief | Children 6–11 yr | 2.5 mg QHS | 2.5 mg QHS | 2.5 mg/24h |
Renal Do not use in consumers with kidney disease (OTC labeling).
Hepatic Undefined
Instructions
- Take once daily in the evening.
- Do not exceed the labeled maximum in 24 hours.
- Adults ≥65 yr: ask a doctor. Children <6 yr: do not use.
- Do not use in kidney disease.
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskSedation, more than loratadine
Cost, est. cash$5–$150/month
Generic entry2010
Classes and tags
Clinical profile
Legacy pregnancy categoryB
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Mechanism of action: Levocetirizine ballicule
Open Levocetirizine in the interactive console ↗
Memory aids: mascots and interaction avatars
